Your browser doesn't support javascript.
loading
ROAR trial: which treatment is effective after progression? - Authors' reply.
Wen, Patrick Y; Burgess, Paul; Ilankumaran, Palanichamy; Subbiah, Vivek.
Afiliação
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: patrick_wen@dfci.harvard.edu.
  • Burgess P; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals, Basel, Switzerland.
  • Ilankumaran P; Global Drug Development, Oncology Development Unit, Novartis Pharma, East Hanover, NJ, USA.
  • Subbiah V; Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol ; 23(3): e94, 2022 03.
Article em En | MEDLINE | ID: mdl-35240095
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article